Takeda’s Dengue Fever Vaccine Holds Up Over 4.5 Years

Takeda announced results from its Phase III clinical trial of TAK-003, its dengue fever vaccine candidate, at the Northern European Conference of Travel Medicine. The data showed that TAK-003 produced protective results through 4 and a half years and helped reduce hospitalizations and symptomatic dengue illness overall.